Mitsubishi UFJ Asset Management Co. Ltd. Purchases 26,671 Shares of Becton, Dickinson and Company $BDX

Key Points

• Mitsubishi UFJ Asset Management increased its position in Becton, Dickinson by 4.4%, acquiring 26,671 shares to hold 627,900 shares valued at about $122.4 million (roughly 0.22% of the company).
• Becton, Dickinson reported quarterly EPS of $2.91, topping estimates of $2.81 while revenue of $4.49 billion missed expectations of $5.15 billion, and it set FY2026 guidance at $12.35–$12.65 per share (consensus ~12.52).
• The board authorized a $10 million share repurchase program and declared a quarterly dividend of $1.05 ($4.20 annualized, ~2.9% yield), with institutional ownership around 87%.

Mitsubishi UFJ Asset Management Co. Ltd. raised its position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 4.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 627,900 shares of the medical instruments supplier's stock after acquiring an additional 26,671 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd. owned about 0.22% of Becton, Dickinson and Company worth $122,403,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. boosted its position in Becton, Dickinson and Company by 13.0% during the fourth quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier's stock valued at $7,118,282,000 after acquiring an additional 4,223,149 shares during the last quarter. State Street Corp raised its holdings in shares of Becton, Dickinson and Company by 3.4% during the third quarter. State Street Corp now owns 13,872,395 shares of the medical instruments supplier's stock valued at $2,596,496,000 after purchasing an additional 459,219 shares during the period. First Eagle Investment Management LLC raised its holdings in shares of Becton, Dickinson and Company by 13.8% during the third quarter. First Eagle Investment Management LLC now owns 9,994,408 shares of the medical instruments supplier's stock valued at $1,870,653,000 after purchasing an additional 1,208,218 shares during the period. Massachusetts Financial Services Co. MA raised its holdings in shares of Becton, Dickinson and Company by 3.7% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 9,486,694 shares of the medical instruments supplier's stock valued at $1,841,083,000 after purchasing an additional 336,110 shares during the period. Finally, Wellington Management Group LLP raised its holdings in shares of Becton, Dickinson and Company by 9,056.3% during the third quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier's stock valued at $979,290,000 after purchasing an additional 5,174,944 shares during the period. Institutional investors own 86.97% of the company's stock.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, Director Bertram L. Scott sold 953 shares of the company's stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total value of $174,027.33. Following the sale, the director owned 36,763 shares in the company, valued at $6,713,291.43. This represents a 2.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In the last quarter, insiders have sold 1,102 shares of company stock valued at $198,909. Corporate insiders own 0.40% of the company's stock.

Becton, Dickinson and Company Trading Up 0.6%

BDX opened at $144.99 on Thursday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.58. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $187.35. The firm has a market capitalization of $41.28 billion, a PE ratio of 23.65, a P/E/G ratio of 10.28 and a beta of 0.22. The company's 50-day moving average is $159.08 and its 200 day moving average is $181.33.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, topping analysts' consensus estimates of $2.81 by $0.10. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The company had revenue of $4.49 billion for the quarter, compared to analyst estimates of $5.15 billion. During the same quarter in the prior year, the business posted $3.43 EPS. The firm's revenue was up 1.6% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. As a group, research analysts predict that Becton, Dickinson and Company will post 12.52 earnings per share for the current fiscal year.

Becton, Dickinson and Company announced that its Board of Directors has initiated a share buyback program on Tuesday, January 27th that permits the company to repurchase $10.00 million in shares. This repurchase authorization permits the medical instruments supplier to purchase up to 0% of its shares through open market purchases. Shares repurchase programs are often a sign that the company's board believes its stock is undervalued.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th will be issued a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date is Tuesday, June 9th. Becton, Dickinson and Company's dividend payout ratio is currently 68.52%.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on BDX shares. Piper Sandler dropped their price objective on shares of Becton, Dickinson and Company from $170.00 to $159.00 and set a "neutral" rating on the stock in a report on Friday, April 17th. Stifel Nicolaus upped their price objective on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a "buy" rating in a report on Wednesday, January 7th. Jefferies Financial Group dropped their price objective on shares of Becton, Dickinson and Company from $220.00 to $190.00 and set a "buy" rating on the stock in a report on Tuesday, February 10th. Evercore started coverage on shares of Becton, Dickinson and Company in a report on Monday. They set an "outperform" rating and a $180.00 price objective on the stock. Finally, Zacks Research upgraded shares of Becton, Dickinson and Company from a "strong sell" rating to a "hold" rating in a report on Friday, April 10th. Seven investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, Becton, Dickinson and Company has an average rating of "Hold" and a consensus price target of $186.57.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.